TORCH infections: Difference between revisions

(Created page with "TORCH infections is an acronym for a group of congenital and perinatal infections that share overlapping clinical features in the newborn: '''T'''oxoplasmosis, '''O'''ther (syphilis, varicella, parvovirus B19, Zika), '''R'''ubella, '''C'''ytomegalovirus (CMV), and '''H'''erpes simplex virus (HSV).<ref name="StatPearls">Jaan A, Rajnik M. TORCH Complex. ''StatPearls''. NCBI. 2023.</ref> These infections account for approximately 2-3% of all congenital anomalies and may cau...")
 
(Moved intro paragraph into Background as bullets; removed excessive bold from bullet lead-ins; bold retained for critical items only)
Line 1: Line 1:
TORCH infections is an acronym for a group of congenital and perinatal infections that share overlapping clinical features in the newborn: '''T'''oxoplasmosis, '''O'''ther (syphilis, varicella, parvovirus B19, Zika), '''R'''ubella, '''C'''ytomegalovirus (CMV), and '''H'''erpes simplex virus (HSV).<ref name="StatPearls">Jaan A, Rajnik M. TORCH Complex. ''StatPearls''. NCBI. 2023.</ref> These infections account for approximately 2-3% of all congenital anomalies and may cause fetal death, prematurity, growth restriction, and devastating multisystem disease.<ref name="StatPearls"/> The emergency physician's role is to '''recognize the nonspecific clinical pattern''' that suggests congenital infection, '''initiate time-sensitive empiric treatment''' (especially acyclovir for HSV), and '''arrange appropriate confirmatory testing and specialist consultation'''.
==Background==
==Background==
*TORCH infections is an acronym for a group of congenital and perinatal infections that share overlapping clinical features in the newborn: Toxoplasmosis, Other (syphilis, varicella, parvovirus B19, Zika), Rubella, Cytomegalovirus (CMV), and Herpes simplex virus (HSV).<ref name="StatPearls">Jaan A, Rajnik M. TORCH Complex. ''StatPearls''. NCBI. 2023.</ref> These infections account for approximately 2-3% of all congenital anomalies and may cause fetal death, prematurity, growth restriction, and devastating multisystem disease.<ref name="StatPearls"/> The emergency physician's role is to recognize the nonspecific clinical pattern that suggests congenital infection, initiate time-sensitive empiric treatment (especially acyclovir for HSV), and arrange appropriate confirmatory testing and specialist consultation.
*TORCH infections are transmitted from mother to fetus/neonate via:
*TORCH infections are transmitted from mother to fetus/neonate via:
**'''Transplacental''' (during pregnancy) — most TORCH agents
** Transplacental (during pregnancy) — most TORCH agents
**'''Peripartum''' (during delivery) — HSV (~85% of neonatal HSV cases), HIV
** Peripartum (during delivery) — HSV (~85% of neonatal HSV cases), HIV
**'''Postpartum''' (breast milk, close contact) — CMV, HIV
** Postpartum (breast milk, close contact) — CMV, HIV
*'''Earlier gestational infection generally causes more severe fetal damage'''; later infection causes higher transmission rates but often milder disease<ref name="AMBOSS">Congenital TORCH infections. ''AMBOSS''. 2024.</ref>
* Earlier gestational infection generally causes more severe fetal damage; later infection causes higher transmission rates but often milder disease<ref name="AMBOSS">Congenital TORCH infections. ''AMBOSS''. 2024.</ref>
*Neonatal cholestasis occurs in ~1 in 2,500 live births; infections account for ~11% of cases (see [[Neonatal hepatitis]])<ref name="Gottesman">Gottesman LE, et al. Etiologies of conjugated hyperbilirubinemia in infancy: systematic review. ''BMC Pediatr''. 2015;15:192.</ref>
*Neonatal cholestasis occurs in ~1 in 2,500 live births; infections account for ~11% of cases (see [[Neonatal hepatitis]])<ref name="Gottesman">Gottesman LE, et al. Etiologies of conjugated hyperbilirubinemia in infancy: systematic review. ''BMC Pediatr''. 2015;15:192.</ref>


Line 12: Line 11:
*A blanket "TORCH titer" panel (IgG screening) is of '''limited clinical utility''' and is '''not recommended as a primary diagnostic strategy'''<ref name="StatPearls"/>
*A blanket "TORCH titer" panel (IgG screening) is of '''limited clinical utility''' and is '''not recommended as a primary diagnostic strategy'''<ref name="StatPearls"/>
*Neonatal IgG largely reflects '''maternal antibodies''' transferred across the placenta and does not confirm neonatal infection
*Neonatal IgG largely reflects '''maternal antibodies''' transferred across the placenta and does not confirm neonatal infection
*'''Pathogen-specific testing''' (IgM, PCR) directed by clinical suspicion is far more useful
* Pathogen-specific testing (IgM, PCR) directed by clinical suspicion is far more useful
*If clinical syndrome suggests congenital infection, '''investigate each pathogen individually''' with the most appropriate rapid diagnostic test
*If clinical syndrome suggests congenital infection, '''investigate each pathogen individually''' with the most appropriate rapid diagnostic test


==Clinical features==
==Clinical features==
===Shared/overlapping features (the congenital infection pattern)===
===Shared/overlapping features (the congenital infection pattern)===
*'''Intrauterine growth restriction (IUGR)/small for gestational age'''
* Intrauterine growth restriction (IUGR)/small for gestational age
*'''Hepatosplenomegaly'''
* Hepatosplenomegaly
*'''Jaundice''' (conjugated hyperbilirubinemia — see [[Neonatal hepatitis]])
* Jaundice (conjugated hyperbilirubinemia — see [[Neonatal hepatitis]])
*'''Petechiae, purpura, or thrombocytopenia''' ("blueberry muffin" rash — dermal erythropoiesis)
* Petechiae, purpura, or thrombocytopenia ("blueberry muffin" rash — dermal erythropoiesis)
*'''Microcephaly'''
* Microcephaly
*'''Chorioretinitis'''
* Chorioretinitis
*'''Sensorineural hearing loss'''
* Sensorineural hearing loss
*'''Intracranial calcifications'''
* Intracranial calcifications
*'''Anemia'''
* Anemia
*'''Seizures'''
* Seizures


Many neonates with congenital infection are '''asymptomatic at birth''' but develop sequelae (hearing loss, developmental delay, chorioretinitis) weeks to years later.<ref name="AMBOSS"/>
Many neonates with congenital infection are '''asymptomatic at birth''' but develop sequelae (hearing loss, developmental delay, chorioretinitis) weeks to years later.<ref name="AMBOSS"/>
Line 36: Line 35:
*Calcifications tend to be '''diffuse/scattered''' (compare CMV: periventricular)
*Calcifications tend to be '''diffuse/scattered''' (compare CMV: periventricular)
*Chorioretinitis is the '''most common late finding''' — may appear months to years after birth
*Chorioretinitis is the '''most common late finding''' — may appear months to years after birth
*'''Macrocephaly''' (from hydrocephalus) distinguishes from most other TORCH agents which cause microcephaly
* Macrocephaly (from hydrocephalus) distinguishes from most other TORCH agents which cause microcephaly
*Most neonates are asymptomatic at birth; untreated disease leads to progressive neurologic and ocular damage
*Most neonates are asymptomatic at birth; untreated disease leads to progressive neurologic and ocular damage
*Maternal risk: cat litter, undercooked meat, contaminated soil/water
*Maternal risk: cat litter, undercooked meat, contaminated soil/water


====Congenital syphilis (''Treponema pallidum'')====
====Congenital syphilis (''Treponema pallidum'')====
*'''Early''' (<2 years): hepatosplenomegaly, jaundice, rhinitis ('''snuffles''' — blood-tinged nasal discharge), '''maculopapular rash''' (palms/soles), osteochondritis/periostitis, generalized lymphadenopathy, '''funisitis''' (inflammation of umbilical cord), condylomata lata
* Early (<2 years): hepatosplenomegaly, jaundice, rhinitis ('''snuffles''' — blood-tinged nasal discharge), '''maculopapular rash''' (palms/soles), osteochondritis/periostitis, generalized lymphadenopathy, '''funisitis''' (inflammation of umbilical cord), condylomata lata
*'''Late''' (>2 years): '''Hutchinson teeth''' (notched, peg-shaped incisors), '''saddle nose''', '''frontal bossing''', '''interstitial keratitis''', '''saber shins''', sensorineural deafness, '''high palatal arch'''
* Late (>2 years): '''Hutchinson teeth''' (notched, peg-shaped incisors), '''saddle nose''', '''frontal bossing''', '''interstitial keratitis''', '''saber shins''', sensorineural deafness, '''high palatal arch'''
*'''Hydrops fetalis''' in severe cases
* Hydrops fetalis in severe cases
*Periostitis may be visible on '''skeletal X-rays''' (an important diagnostic clue)
*Periostitis may be visible on '''skeletal X-rays''' (an important diagnostic clue)


Line 51: Line 50:
*Hepatosplenomegaly, thrombocytopenic purpura
*Hepatosplenomegaly, thrombocytopenic purpura
*Microcephaly, intellectual disability
*Microcephaly, intellectual disability
*'''Deafness''' is the most common single manifestation
* Deafness is the most common single manifestation
*Rare in countries with effective vaccination programs; consider in unvaccinated/immigrant populations
*Rare in countries with effective vaccination programs; consider in unvaccinated/immigrant populations


====Cytomegalovirus (CMV) — the most common congenital infection====
====Cytomegalovirus (CMV) — the most common congenital infection====
*Most common congenital infection worldwide (~0.2-2% of live births)<ref name="AMBOSS"/>
*Most common congenital infection worldwide (~0.2-2% of live births)<ref name="AMBOSS"/>
*'''~90% are asymptomatic at birth''' — but asymptomatic infants can still develop late-onset hearing loss and developmental delay
* ~90% are asymptomatic at birth — but asymptomatic infants can still develop late-onset hearing loss and developmental delay
*Symptomatic disease: petechiae, hepatosplenomegaly, jaundice, microcephaly, '''periventricular calcifications''' (compare toxoplasmosis: diffuse), chorioretinitis, seizures
*Symptomatic disease: petechiae, hepatosplenomegaly, jaundice, microcephaly, '''periventricular calcifications''' (compare toxoplasmosis: diffuse), chorioretinitis, seizures
*'''Sensorineural hearing loss''' is the most important late complication — leading infectious cause of childhood hearing loss worldwide
* Sensorineural hearing loss is the most important late complication — leading infectious cause of childhood hearing loss worldwide
*"Blueberry muffin" rash
*"Blueberry muffin" rash


====Herpes simplex virus (HSV) — the most acutely life-threatening====
====Herpes simplex virus (HSV) — the most acutely life-threatening====
*'''Most EM-critical TORCH infection''' due to rapid progression and high mortality without treatment<ref name="HSV_JHM">Schmit M, et al. Clinical progress note: Evaluation and management of neonatal herpes simplex virus disease. ''J Hosp Med''. 2023;18(6):548-555.</ref>
* Most EM-critical TORCH infection due to rapid progression and high mortality without treatment<ref name="HSV_JHM">Schmit M, et al. Clinical progress note: Evaluation and management of neonatal herpes simplex virus disease. ''J Hosp Med''. 2023;18(6):548-555.</ref>
*Incidence: ~1 in 2,000-3,200 live births in the US
*Incidence: ~1 in 2,000-3,200 live births in the US
*~85% acquired '''peripartum''' (during delivery), ~10% postpartum, ~5% in utero
*~85% acquired '''peripartum''' (during delivery), ~10% postpartum, ~5% in utero
*'''Three clinical categories:'''
* Three clinical categories:


{| class="wikitable"
{| class="wikitable"
Line 78: Line 77:
|}
|}


*'''Critical pitfall:''' vesicular rash is '''absent''' in ~40% of CNS and disseminated disease — '''do not rely on vesicles to suspect HSV'''<ref name="HSV_JHM"/>
* Critical pitfall: vesicular rash is '''absent''' in ~40% of CNS and disseminated disease — '''do not rely on vesicles to suspect HSV'''<ref name="HSV_JHM"/>
*'''Fever is often absent at presentation'''
* Fever is often absent at presentation
*'''Any ill neonate <42 days of age with sepsis-like picture, seizures, or liver failure should be empirically treated with acyclovir'''
*'''Any ill neonate <42 days of age with sepsis-like picture, seizures, or liver failure should be empirically treated with acyclovir'''


====Other "O" pathogens====
====Other "O" pathogens====
*'''Parvovirus B19:''' severe fetal anemia → '''hydrops fetalis''' (nonimmune); aplastic crisis; usually self-limited if live-born; may require intrauterine transfusion
* Parvovirus B19: severe fetal anemia → '''hydrops fetalis''' (nonimmune); aplastic crisis; usually self-limited if live-born; may require intrauterine transfusion
*'''Varicella (VZV):''' congenital varicella syndrome (limb hypoplasia, cicatricial skin lesions, microcephaly, cortical atrophy, chorioretinitis); very rare with maternal vaccination
* Varicella (VZV): congenital varicella syndrome (limb hypoplasia, cicatricial skin lesions, microcephaly, cortical atrophy, chorioretinitis); very rare with maternal vaccination
*'''Zika virus:''' microcephaly (often severe), ocular defects, arthrogryposis; epidemic setting; no specific treatment
* Zika virus: microcephaly (often severe), ocular defects, arthrogryposis; epidemic setting; no specific treatment
*'''HIV:''' usually asymptomatic at birth; testing and prophylaxis per neonatal protocols
* HIV: usually asymptomatic at birth; testing and prophylaxis per neonatal protocols


==Differential diagnosis==
==Differential diagnosis==
===Neonate with the "congenital infection" pattern===
===Neonate with the "congenital infection" pattern===
*'''Other TORCH infections''' (always consider the full panel when one is suspected)
* Other TORCH infections (always consider the full panel when one is suspected)
*[[Neonatal sepsis]] (bacterial — ''E. coli'', GBS)
*[[Neonatal sepsis]] (bacterial — ''E. coli'', GBS)
*[[Galactosemia]] (may mimic sepsis with liver failure; ''E. coli'' sepsis association)
*[[Galactosemia]] (may mimic sepsis with liver failure; ''E. coli'' sepsis association)
Line 102: Line 101:
==Evaluation==
==Evaluation==
===ED workup for suspected congenital infection===
===ED workup for suspected congenital infection===
*'''CBC with differential:''' anemia, thrombocytopenia, atypical lymphocytes, neutropenia
* CBC with differential: anemia, thrombocytopenia, atypical lymphocytes, neutropenia
*'''Hepatic panel:''' AST, ALT (may be markedly elevated in HSV hepatitis), bilirubin (fractionate)
* Hepatic panel: AST, ALT (may be markedly elevated in HSV hepatitis), bilirubin (fractionate)
*'''Coagulation studies:''' PT/INR, fibrinogen (DIC in disseminated HSV)
* Coagulation studies: PT/INR, fibrinogen (DIC in disseminated HSV)
*'''Blood glucose:''' hypoglycemia (hepatic failure)
* Blood glucose: hypoglycemia (hepatic failure)
*'''BMP:''' electrolytes, renal function
* BMP: electrolytes, renal function
*'''Blood culture''' (to exclude bacterial sepsis)
* Blood culture (to exclude bacterial sepsis)
*'''Urinalysis and urine culture'''
* Urinalysis and urine culture
*'''Lumbar puncture:''' CSF cell count, protein, glucose, HSV PCR, bacterial culture; HSV PCR on CSF is critical for diagnosis of CNS disease
* Lumbar puncture: CSF cell count, protein, glucose, HSV PCR, bacterial culture; HSV PCR on CSF is critical for diagnosis of CNS disease
*'''ALT specifically:''' markedly elevated ALT is a red flag for disseminated HSV (liver is a primary target organ)
* ALT specifically: markedly elevated ALT is a red flag for disseminated HSV (liver is a primary target organ)


===Pathogen-specific testing (initiate from ED based on clinical suspicion)===
===Pathogen-specific testing (initiate from ED based on clinical suspicion)===
Line 132: Line 131:


===Imaging===
===Imaging===
*'''Cranial ultrasound''' (neonates): intracranial calcifications, ventriculomegaly, periventricular echogenicity
* Cranial ultrasound (neonates): intracranial calcifications, ventriculomegaly, periventricular echogenicity
*'''CT head:''' more sensitive for calcifications; periventricular (CMV) vs diffuse (toxoplasmosis) distribution pattern
* CT head: more sensitive for calcifications; periventricular (CMV) vs diffuse (toxoplasmosis) distribution pattern
*'''MRI brain:''' most sensitive for cortical malformations (polymicrogyria in CMV), white matter disease
* MRI brain: most sensitive for cortical malformations (polymicrogyria in CMV), white matter disease
*'''Ophthalmologic examination:''' all suspected congenital infections require fundoscopic exam for chorioretinitis
* Ophthalmologic examination: all suspected congenital infections require fundoscopic exam for chorioretinitis
*'''Skeletal survey:''' periostitis, osteochondritis (congenital syphilis)
* Skeletal survey: periostitis, osteochondritis (congenital syphilis)
*'''Audiology (ABR):''' arrange for all confirmed congenital infections, especially CMV
* Audiology (ABR): arrange for all confirmed congenital infections, especially CMV


==Management==
==Management==
===HSV — the ED emergency===
===HSV — the ED emergency===
*'''Start IV acyclovir immediately''' in any neonate with suspected HSV — '''do not wait for PCR results'''<ref name="HSV_JHM"/>
*'''Start IV acyclovir immediately''' in any neonate with suspected HSV — '''do not wait for PCR results'''<ref name="HSV_JHM"/>
*'''Dose: acyclovir 20 mg/kg/dose IV every 8 hours''' (= 60 mg/kg/day)
* Dose: acyclovir 20 mg/kg/dose IV every 8 hours (= 60 mg/kg/day)
*'''Duration:'''
* Duration:
**'''SEM disease: 14 days''' IV
** SEM disease: 14 days IV
**'''CNS or disseminated disease: 21 days''' IV
** CNS or disseminated disease: 21 days IV
**Repeat LP with CSF HSV PCR before stopping treatment in CNS disease; '''continue IV acyclovir until CSF PCR is negative'''<ref name="HSV_NIH">Herpes Simplex Virus: Pediatric OIs. ''NIH Clinical Guidelines''. 2024.</ref>
**Repeat LP with CSF HSV PCR before stopping treatment in CNS disease; '''continue IV acyclovir until CSF PCR is negative'''<ref name="HSV_NIH">Herpes Simplex Virus: Pediatric OIs. ''NIH Clinical Guidelines''. 2024.</ref>
*After IV course: '''oral acyclovir suppressive therapy''' 300 mg/m²/dose TID for '''6 months''' (reduces cutaneous recurrences and improves neurodevelopmental outcomes in CNS disease)
*After IV course: '''oral acyclovir suppressive therapy''' 300 mg/m²/dose TID for '''6 months''' (reduces cutaneous recurrences and improves neurodevelopmental outcomes in CNS disease)
*'''Supportive care:''' IV fluids, correct DIC/coagulopathy (FFP, cryoprecipitate, platelets), respiratory support, seizure management, broad-spectrum antibiotics until bacterial sepsis excluded
* Supportive care: IV fluids, correct DIC/coagulopathy (FFP, cryoprecipitate, platelets), respiratory support, seizure management, broad-spectrum antibiotics until bacterial sepsis excluded
*'''Monitor:''' CBC twice weekly (acyclovir-associated neutropenia in ~20%), daily creatinine (nephrotoxicity)
* Monitor: CBC twice weekly (acyclovir-associated neutropenia in ~20%), daily creatinine (nephrotoxicity)
*'''Ophthalmology consult:''' herpetic keratoconjunctivitis requires topical trifluridine or ganciclovir in addition to systemic therapy
* Ophthalmology consult: herpetic keratoconjunctivitis requires topical trifluridine or ganciclovir in addition to systemic therapy


===Congenital syphilis===
===Congenital syphilis===
*'''Aqueous penicillin G: 50,000 units/kg/dose IV every 12 hours''' (age <7 days) or '''every 8 hours''' (age ≥7 days) for '''10 days'''<ref name="StatPearls"/>
* Aqueous penicillin G: 50,000 units/kg/dose IV every 12 hours (age <7 days) or '''every 8 hours''' (age ≥7 days) for '''10 days'''<ref name="StatPearls"/>
*Alternative: '''Procaine penicillin G 50,000 units/kg IM daily''' for 10 days (if IV not feasible)
*Alternative: '''Procaine penicillin G 50,000 units/kg IM daily''' for 10 days (if IV not feasible)
*Normal neonate born to adequately treated mother (≥4 weeks before delivery): single dose '''benzathine penicillin G 50,000 units/kg IM''' may suffice
*Normal neonate born to adequately treated mother (≥4 weeks before delivery): single dose '''benzathine penicillin G 50,000 units/kg IM''' may suffice
*'''No alternative to penicillin''' — penicillin-allergic infants require desensitization
* No alternative to penicillin — penicillin-allergic infants require desensitization


===Congenital toxoplasmosis===
===Congenital toxoplasmosis===
*'''Pyrimethamine''' (loading dose 2 mg/kg/day for 2 days, then 1 mg/kg/day) + '''sulfadiazine''' (50 mg/kg/dose BID) + '''leucovorin''' (10 mg 3 times weekly) for '''12 months'''<ref name="CDC_Toxo">Clinical Care of Toxoplasmosis. ''CDC''. 2024.</ref>
* Pyrimethamine (loading dose 2 mg/kg/day for 2 days, then 1 mg/kg/day) + '''sulfadiazine''' (50 mg/kg/dose BID) + '''leucovorin''' (10 mg 3 times weekly) for '''12 months'''<ref name="CDC_Toxo">Clinical Care of Toxoplasmosis. ''CDC''. 2024.</ref>
*Leucovorin (folinic acid) is '''mandatory''' to prevent pyrimethamine-induced bone marrow suppression
*Leucovorin (folinic acid) is '''mandatory''' to prevent pyrimethamine-induced bone marrow suppression
*'''Do NOT substitute folic acid for leucovorin''' — folic acid antagonizes pyrimethamine's therapeutic effect while leucovorin selectively rescues marrow
*'''Do NOT substitute folic acid for leucovorin''' — folic acid antagonizes pyrimethamine's therapeutic effect while leucovorin selectively rescues marrow
*Add '''corticosteroids''' (prednisone 0.5 mg/kg BID) if CSF protein >1 g/dL or vision-threatening chorioretinitis
*Add '''corticosteroids''' (prednisone 0.5 mg/kg BID) if CSF protein >1 g/dL or vision-threatening chorioretinitis
*'''Weekly CBC''' while on pyrimethamine (monitor for neutropenia, anemia, thrombocytopenia)
* Weekly CBC while on pyrimethamine (monitor for neutropenia, anemia, thrombocytopenia)


===Congenital CMV===
===Congenital CMV===
*'''Valganciclovir''' (oral) or '''ganciclovir''' (IV) for moderate-to-severe symptomatic congenital CMV<ref name="AMBOSS"/>
* Valganciclovir (oral) or '''ganciclovir''' (IV) for moderate-to-severe symptomatic congenital CMV<ref name="AMBOSS"/>
*Valganciclovir 16 mg/kg/dose BID orally for 6 months is current standard
*Valganciclovir 16 mg/kg/dose BID orally for 6 months is current standard
*Goal is to preserve hearing and neurodevelopmental outcomes
*Goal is to preserve hearing and neurodevelopmental outcomes
*'''Not routinely initiated in the ED''' — refer to infectious disease/neonatology for treatment decisions
* Not routinely initiated in the ED — refer to infectious disease/neonatology for treatment decisions
*Monitor for neutropenia, thrombocytopenia, hepatotoxicity
*Monitor for neutropenia, thrombocytopenia, hepatotoxicity


===Congenital rubella===
===Congenital rubella===
*'''No specific antiviral treatment'''
* No specific antiviral treatment
*Supportive management of cardiac defects, cataracts, hearing loss
*Supportive management of cardiac defects, cataracts, hearing loss
*'''Infectious for up to 1 year''' — isolation precautions; notify public health
* Infectious for up to 1 year — isolation precautions; notify public health


===General supportive measures for all congenital infections===
===General supportive measures for all congenital infections===
Line 187: Line 186:


==Disposition==
==Disposition==
*'''All neonates with suspected congenital infection should be admitted''' — most will require NICU-level care
* All neonates with suspected congenital infection should be admitted — most will require NICU-level care
*'''HSV:''' start acyclovir in the ED; admit to NICU; infectious disease consultation
* HSV: start acyclovir in the ED; admit to NICU; infectious disease consultation
*'''Syphilis with positive RPR or symptomatic:''' admit; start IV penicillin after LP; involve infectious disease
* Syphilis with positive RPR or symptomatic: admit; start IV penicillin after LP; involve infectious disease
*'''CMV, toxoplasmosis:''' admit for confirmatory testing, neuroimaging, ophthalmologic evaluation, and treatment initiation
* CMV, toxoplasmosis: admit for confirmatory testing, neuroimaging, ophthalmologic evaluation, and treatment initiation
*'''Well-appearing infant with isolated conjugated hyperbilirubinemia:''' may be evaluated urgently as outpatient (see [[Neonatal hepatitis]]) but ensure TORCH-specific testing is sent and follow-up is reliable
* Well-appearing infant with isolated conjugated hyperbilirubinemia: may be evaluated urgently as outpatient (see [[Neonatal hepatitis]]) but ensure TORCH-specific testing is sent and follow-up is reliable
*'''Notify:''' congenital syphilis and rubella are '''reportable diseases''' — contact public health
* Notify: congenital syphilis and rubella are '''reportable diseases''' — contact public health


==See Also==
==See Also==

Revision as of 14:18, 19 March 2026

Background

  • TORCH infections is an acronym for a group of congenital and perinatal infections that share overlapping clinical features in the newborn: Toxoplasmosis, Other (syphilis, varicella, parvovirus B19, Zika), Rubella, Cytomegalovirus (CMV), and Herpes simplex virus (HSV).[1] These infections account for approximately 2-3% of all congenital anomalies and may cause fetal death, prematurity, growth restriction, and devastating multisystem disease.[1] The emergency physician's role is to recognize the nonspecific clinical pattern that suggests congenital infection, initiate time-sensitive empiric treatment (especially acyclovir for HSV), and arrange appropriate confirmatory testing and specialist consultation.
  • TORCH infections are transmitted from mother to fetus/neonate via:
    • Transplacental (during pregnancy) — most TORCH agents
    • Peripartum (during delivery) — HSV (~85% of neonatal HSV cases), HIV
    • Postpartum (breast milk, close contact) — CMV, HIV
  • Earlier gestational infection generally causes more severe fetal damage; later infection causes higher transmission rates but often milder disease[2]
  • Neonatal cholestasis occurs in ~1 in 2,500 live births; infections account for ~11% of cases (see Neonatal hepatitis)[3]

The "TORCH titer" — limitations

  • A blanket "TORCH titer" panel (IgG screening) is of limited clinical utility and is not recommended as a primary diagnostic strategy[1]
  • Neonatal IgG largely reflects maternal antibodies transferred across the placenta and does not confirm neonatal infection
  • Pathogen-specific testing (IgM, PCR) directed by clinical suspicion is far more useful
  • If clinical syndrome suggests congenital infection, investigate each pathogen individually with the most appropriate rapid diagnostic test

Clinical features

Shared/overlapping features (the congenital infection pattern)

  • Intrauterine growth restriction (IUGR)/small for gestational age
  • Hepatosplenomegaly
  • Jaundice (conjugated hyperbilirubinemia — see Neonatal hepatitis)
  • Petechiae, purpura, or thrombocytopenia ("blueberry muffin" rash — dermal erythropoiesis)
  • Microcephaly
  • Chorioretinitis
  • Sensorineural hearing loss
  • Intracranial calcifications
  • Anemia
  • Seizures

Many neonates with congenital infection are asymptomatic at birth but develop sequelae (hearing loss, developmental delay, chorioretinitis) weeks to years later.[2]

Pathogen-specific features

Toxoplasmosis (Toxoplasma gondii)

  • Classic triad: chorioretinitis + hydrocephalus + diffuse intracranial calcifications[1]
  • Calcifications tend to be diffuse/scattered (compare CMV: periventricular)
  • Chorioretinitis is the most common late finding — may appear months to years after birth
  • Macrocephaly (from hydrocephalus) distinguishes from most other TORCH agents which cause microcephaly
  • Most neonates are asymptomatic at birth; untreated disease leads to progressive neurologic and ocular damage
  • Maternal risk: cat litter, undercooked meat, contaminated soil/water

Congenital syphilis (Treponema pallidum)

  • Early (<2 years): hepatosplenomegaly, jaundice, rhinitis (snuffles — blood-tinged nasal discharge), maculopapular rash (palms/soles), osteochondritis/periostitis, generalized lymphadenopathy, funisitis (inflammation of umbilical cord), condylomata lata
  • Late (>2 years): Hutchinson teeth (notched, peg-shaped incisors), saddle nose, frontal bossing, interstitial keratitis, saber shins, sensorineural deafness, high palatal arch
  • Hydrops fetalis in severe cases
  • Periostitis may be visible on skeletal X-rays (an important diagnostic clue)

Rubella (congenital rubella syndrome)

  • Classic triad: sensorineural deafness + cataracts + congenital heart disease (especially patent ductus arteriosus, pulmonary artery stenosis)[2]
  • "Blueberry muffin" rash (dermal erythropoiesis)
  • Hepatosplenomegaly, thrombocytopenic purpura
  • Microcephaly, intellectual disability
  • Deafness is the most common single manifestation
  • Rare in countries with effective vaccination programs; consider in unvaccinated/immigrant populations

Cytomegalovirus (CMV) — the most common congenital infection

  • Most common congenital infection worldwide (~0.2-2% of live births)[2]
  • ~90% are asymptomatic at birth — but asymptomatic infants can still develop late-onset hearing loss and developmental delay
  • Symptomatic disease: petechiae, hepatosplenomegaly, jaundice, microcephaly, periventricular calcifications (compare toxoplasmosis: diffuse), chorioretinitis, seizures
  • Sensorineural hearing loss is the most important late complication — leading infectious cause of childhood hearing loss worldwide
  • "Blueberry muffin" rash

Herpes simplex virus (HSV) — the most acutely life-threatening

  • Most EM-critical TORCH infection due to rapid progression and high mortality without treatment[4]
  • Incidence: ~1 in 2,000-3,200 live births in the US
  • ~85% acquired peripartum (during delivery), ~10% postpartum, ~5% in utero
  • Three clinical categories:
Category Frequency Typical onset Key features Mortality (with treatment)
SEM (skin, eyes, mouth) ~45% Day 7-14 Vesicular rash (>80% have vesicles), keratoconjunctivitis, oral ulcers <1%
CNS ~30% Day 14-21 Seizures (often focal), irritability, lethargy, poor feeding, bulging fontanelle; vesicles in only ~60% ~4%
Disseminated ~25% Day 7-14 Sepsis-like: DIC, hepatitis/liver failure, pneumonitis, shock; CNS involved in up to 75%; vesicles in only ~60% ~30%
  • Critical pitfall: vesicular rash is absent in ~40% of CNS and disseminated disease — do not rely on vesicles to suspect HSV[4]
  • Fever is often absent at presentation
  • Any ill neonate <42 days of age with sepsis-like picture, seizures, or liver failure should be empirically treated with acyclovir

Other "O" pathogens

  • Parvovirus B19: severe fetal anemia → hydrops fetalis (nonimmune); aplastic crisis; usually self-limited if live-born; may require intrauterine transfusion
  • Varicella (VZV): congenital varicella syndrome (limb hypoplasia, cicatricial skin lesions, microcephaly, cortical atrophy, chorioretinitis); very rare with maternal vaccination
  • Zika virus: microcephaly (often severe), ocular defects, arthrogryposis; epidemic setting; no specific treatment
  • HIV: usually asymptomatic at birth; testing and prophylaxis per neonatal protocols

Differential diagnosis

Neonate with the "congenital infection" pattern

  • Other TORCH infections (always consider the full panel when one is suspected)
  • Neonatal sepsis (bacterial — E. coli, GBS)
  • Galactosemia (may mimic sepsis with liver failure; E. coli sepsis association)
  • Tyrosinemia type 1 (liver failure + coagulopathy)
  • Neonatal hemochromatosis (GALD)
  • Biliary atresia (if jaundice is the presenting sign)
  • Neonatal leukemia/neuroblastoma ("blueberry muffin" appearance)
  • Hemophagocytic lymphohistiocytosis (HLH)
  • Aicardi-Goutières syndrome (pseudo-TORCH — genetic condition mimicking congenital infection with calcifications + CSF lymphocytosis)

Evaluation

ED workup for suspected congenital infection

  • CBC with differential: anemia, thrombocytopenia, atypical lymphocytes, neutropenia
  • Hepatic panel: AST, ALT (may be markedly elevated in HSV hepatitis), bilirubin (fractionate)
  • Coagulation studies: PT/INR, fibrinogen (DIC in disseminated HSV)
  • Blood glucose: hypoglycemia (hepatic failure)
  • BMP: electrolytes, renal function
  • Blood culture (to exclude bacterial sepsis)
  • Urinalysis and urine culture
  • Lumbar puncture: CSF cell count, protein, glucose, HSV PCR, bacterial culture; HSV PCR on CSF is critical for diagnosis of CNS disease
  • ALT specifically: markedly elevated ALT is a red flag for disseminated HSV (liver is a primary target organ)

Pathogen-specific testing (initiate from ED based on clinical suspicion)

Pathogen Best diagnostic test Key notes
HSV HSV PCR (CSF, blood, surface swabs of mouth/eyes/nasopharynx/vesicles) Start acyclovir empirically before results return; also send ALT, DIC labs
CMV Urine CMV PCR or saliva CMV PCR Must be collected within first 3 weeks of life to distinguish congenital from postnatal infection
Toxoplasmosis Toxoplasma-specific IgM and IgA in infant serum; PCR IgG alone reflects maternal antibodies; ophthalmology and neuroimaging needed
Syphilis RPR/VDRL (quantitative) on infant AND mother; treponemal test (FTA-ABS IgM) Compare infant to maternal RPR titers; skeletal survey; LP if neurosyphilis suspected
Rubella Rubella-specific IgM in infant serum Maternal vaccination history is critical; viral culture/PCR of nasopharyngeal secretions
Parvovirus B19 Parvovirus IgM; PCR on blood Reticulocyte count (aplastic crisis); fetal ultrasound for hydrops

Imaging

  • Cranial ultrasound (neonates): intracranial calcifications, ventriculomegaly, periventricular echogenicity
  • CT head: more sensitive for calcifications; periventricular (CMV) vs diffuse (toxoplasmosis) distribution pattern
  • MRI brain: most sensitive for cortical malformations (polymicrogyria in CMV), white matter disease
  • Ophthalmologic examination: all suspected congenital infections require fundoscopic exam for chorioretinitis
  • Skeletal survey: periostitis, osteochondritis (congenital syphilis)
  • Audiology (ABR): arrange for all confirmed congenital infections, especially CMV

Management

HSV — the ED emergency

  • Start IV acyclovir immediately in any neonate with suspected HSV — do not wait for PCR results[4]
  • Dose: acyclovir 20 mg/kg/dose IV every 8 hours (= 60 mg/kg/day)
  • Duration:
    • SEM disease: 14 days IV
    • CNS or disseminated disease: 21 days IV
    • Repeat LP with CSF HSV PCR before stopping treatment in CNS disease; continue IV acyclovir until CSF PCR is negative[5]
  • After IV course: oral acyclovir suppressive therapy 300 mg/m²/dose TID for 6 months (reduces cutaneous recurrences and improves neurodevelopmental outcomes in CNS disease)
  • Supportive care: IV fluids, correct DIC/coagulopathy (FFP, cryoprecipitate, platelets), respiratory support, seizure management, broad-spectrum antibiotics until bacterial sepsis excluded
  • Monitor: CBC twice weekly (acyclovir-associated neutropenia in ~20%), daily creatinine (nephrotoxicity)
  • Ophthalmology consult: herpetic keratoconjunctivitis requires topical trifluridine or ganciclovir in addition to systemic therapy

Congenital syphilis

  • Aqueous penicillin G: 50,000 units/kg/dose IV every 12 hours (age <7 days) or every 8 hours (age ≥7 days) for 10 days[1]
  • Alternative: Procaine penicillin G 50,000 units/kg IM daily for 10 days (if IV not feasible)
  • Normal neonate born to adequately treated mother (≥4 weeks before delivery): single dose benzathine penicillin G 50,000 units/kg IM may suffice
  • No alternative to penicillin — penicillin-allergic infants require desensitization

Congenital toxoplasmosis

  • Pyrimethamine (loading dose 2 mg/kg/day for 2 days, then 1 mg/kg/day) + sulfadiazine (50 mg/kg/dose BID) + leucovorin (10 mg 3 times weekly) for 12 months[6]
  • Leucovorin (folinic acid) is mandatory to prevent pyrimethamine-induced bone marrow suppression
  • Do NOT substitute folic acid for leucovorin — folic acid antagonizes pyrimethamine's therapeutic effect while leucovorin selectively rescues marrow
  • Add corticosteroids (prednisone 0.5 mg/kg BID) if CSF protein >1 g/dL or vision-threatening chorioretinitis
  • Weekly CBC while on pyrimethamine (monitor for neutropenia, anemia, thrombocytopenia)

Congenital CMV

  • Valganciclovir (oral) or ganciclovir (IV) for moderate-to-severe symptomatic congenital CMV[2]
  • Valganciclovir 16 mg/kg/dose BID orally for 6 months is current standard
  • Goal is to preserve hearing and neurodevelopmental outcomes
  • Not routinely initiated in the ED — refer to infectious disease/neonatology for treatment decisions
  • Monitor for neutropenia, thrombocytopenia, hepatotoxicity

Congenital rubella

  • No specific antiviral treatment
  • Supportive management of cardiac defects, cataracts, hearing loss
  • Infectious for up to 1 year — isolation precautions; notify public health

General supportive measures for all congenital infections

  • Vitamin K (if cholestatic — fat-soluble vitamin malabsorption)
  • Treat conjugated hyperbilirubinemia per workup
  • Nutritional support (MCT-enriched formula if cholestatic)
  • Seizure management
  • Hearing evaluation (ABR) for all
  • Ophthalmologic examination for all
  • Developmental follow-up

Disposition

  • All neonates with suspected congenital infection should be admitted — most will require NICU-level care
  • HSV: start acyclovir in the ED; admit to NICU; infectious disease consultation
  • Syphilis with positive RPR or symptomatic: admit; start IV penicillin after LP; involve infectious disease
  • CMV, toxoplasmosis: admit for confirmatory testing, neuroimaging, ophthalmologic evaluation, and treatment initiation
  • Well-appearing infant with isolated conjugated hyperbilirubinemia: may be evaluated urgently as outpatient (see Neonatal hepatitis) but ensure TORCH-specific testing is sent and follow-up is reliable
  • Notify: congenital syphilis and rubella are reportable diseases — contact public health

See Also

External Links

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 Jaan A, Rajnik M. TORCH Complex. StatPearls. NCBI. 2023.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 Congenital TORCH infections. AMBOSS. 2024.
  3. ↑ Gottesman LE, et al. Etiologies of conjugated hyperbilirubinemia in infancy: systematic review. BMC Pediatr. 2015;15:192.
  4. ↑ 4.0 4.1 4.2 Schmit M, et al. Clinical progress note: Evaluation and management of neonatal herpes simplex virus disease. J Hosp Med. 2023;18(6):548-555.
  5. ↑ Herpes Simplex Virus: Pediatric OIs. NIH Clinical Guidelines. 2024.
  6. ↑ Clinical Care of Toxoplasmosis. CDC. 2024.
Retrieved from "https://www.wikem.org/w/index.php?title=TORCH_infections&oldid=386205"